SCHEMBL31396451

SCHEMBL31396451

Cc1cc(C(N)=O)cc(C)c1-c1ccnc(N)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 9/20 0.48
CDC7 O00311 9/20 0.46
CDK2 P24941 4/20 0.46
ROCK1 Q13464 3/20 0.46
CDK1 P06493 2/20 0.46
GSK3B P49841 2/20 0.46
TAOK1 Q7L7X3 2/20 0.46
PLK4 O00444 1/20 0.46
MAPK13 O15264 1/20 0.46
PDPK1 O15530 1/20 0.46
DAPK3 O43293 1/20 0.46
DYRK3 O43781 1/20 0.46
ROCK2 O75116 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
PRKCG P05129 1/20 0.46
PIM1 P11309 1/20 0.46
FGFR1 P11362 1/20 0.46
PRKACA P17612 1/20 0.46
MARK3 P27448 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3792630 0.82 CDC7 (0.47) JAK2CDC7CDK2ROCK1CDK1
SCHEMBL3393995 0.77 HSP90AA1 (0.55) JAK2CDC7CDK2ROCK1CDK1
SCHEMBL10831613 0.72 PARP1 (0.46)
SCHEMBL5000417 0.72 CDC7 (0.51) JAK2CDC7CDK2ROCK1CDK1
SCHEMBL3658282 0.71 MKNK1 (0.54) JAK2CDC7CDK2ROCK1GSK3B
SCHEMBL27932338 0.70 CDC7 (0.47) JAK2CDC7CDK2ROCK1CDK1
SCHEMBL28557204 0.69 CYP1A2 (0.42) JAK2CDK2ROCK1PRKACACDK5
SCHEMBL3792633 0.67 HSP90AA1 (0.47) CDK2ROCK1GSK3BPDPK1PIM1
SCHEMBL22807531 0.67 KDM5C (0.63) PRKACA
SCHEMBL1004660 0.66 PARP1 (0.50) PRKACAIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12208098-B2 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2025-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12208098-B2 4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof SLC5A1, SLC10A1, DPP4 JAK2 319/4885CDC7 4671/4885CDK2 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.